6IVA Stock Chart & Stats
€3.74
-€0.06(-1.58%)
At close: 4:00 PM EDT
€3.74
-€0.06(-1.58%)
Day’s Range― - ―
52-Week Range€2.74 - €6.20
Previous CloseN/A
Volume0.00
Average Volume (3M)269.00
Market Cap
€897.69M
Enterprise Value€851.70
Total Cash (Recent Filing)€99.27M
Total Debt (Recent Filing)€59.40M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Sep 25, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding236,280,200
10 Day Avg. Volume607
30 Day Avg. Volume269
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-29.92
Price to Sales (P/S)193.76
P/FCF Ratio-8.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.01Price Target Upside247.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.67
Revenue Forecast (FY)€5.95M
Bulls Say, Bears Say
Bulls Say
Phase III Enrollment Completed & >90% PoweringCompleting NATiV3 enrollment and securing >90% statistical power materially reduces execution and enrollment risk over the next 6–12 months. A fully enrolled, well‑powered pivotal trial makes the scheduled Q4 2026 readout more predictable and lowers the chance of inconclusive results due to underpowering or major delays.
Material Cash Balance From Recent FinancingsA sizeable cash position funded by recent equity and structured financings provides multi‑month runway to advance the pivotal program and regulatory planning. This liquidity supports trial completion, NDA preparation and targeted pre‑commercial investments without immediate dependence on revenue or partnering.
Refinancing Reshaped Capital Structure And Repaid EIB LoansRepaying legacy EIB debt and repurchasing onerous warrants simplifies the capital structure and reduces restrictive terms. New debt and equity raises provide immediate funding while the restructured instruments and bondholder protections improve financing flexibility and lower the probability of legacy anti‑dilution constraints affecting future raises.
Bears Say
Negative Shareholder Equity & Rising DebtA transition to negative equity and materially higher debt levels weakens balance‑sheet resilience and long‑term optionality. This structural leverage increases refinancing needs, elevates covenants and investor sensitivity, and can force dilutive financing or constrained strategic choices if clinical or commercial progress falters.
Persistent Cash Burn And Negative Operating Cash FlowSustained negative operating and free cash flow signals ongoing reliance on external capital to fund R&D and operations. Elevated burn increases the probability of additional financings before commercialization, creating recurring dilution risk and making medium‑term strategy contingent on successful trial outcomes or asset monetization.
Tolerability, Endpoint Variability And Competitive PressureClass‑linked tolerability (weight gain, fluid retention), endpoint placebo variability and active competitors create persistent regulatory and market risks. Even with positive efficacy, safety labels or modest margins versus rivals can restrict adoption, complicate labeling discussions and reduce commercial potential over multiple years.
Inventiva News
6IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was €2.74 and its highest was €6.20 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is €897.69M.
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Sep 25, 2026 which is in 53 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Mar 30, 2026. The company reported -€0.925 earnings per share for the quarter, missing the consensus estimate of -€0.242 by -€0.683.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.33.
How many shares outstanding does Inventiva have?
Inventiva has 236,280,200 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -€0.925 in its last earnings report, missing expectations of -€0.242. Following the earnings report the stock price went down -6.809%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in DE:6IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inventiva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€13.01 (247.77% Upside)
€13.01 (247.77% Upside)
Blogger Sentiment
Bullish
DE:6IVA Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
31.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
138.07%
Trailing 12-Months
Company Description
Inventiva
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
6IVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive and execution-focused picture: major operational milestones were achieved (NATiV3 enrollment completion, >1,000 patients, clear Q4 2026 readout target), a solid near-term cash position (EUR 230.9M), conservative powering (>90%) and organizational strengthening for regulatory/commercial readiness. Key risks remain—funding beyond the stated runway depends on tranche/warrant mechanics or future financing, tolerability (weight gain/fluid retention) is a known class risk to be monitored, endpoints have inherent variability, and competition is active. On balance the call emphasized progress, readiness and a clear pathway to a potentially pivotal readout while acknowledging material clinical and financing dependencies.View all DE:6IVA earnings summaries6IVA Stock 12 Month Forecast
Average Price Target
€13.01
▲(247.77% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Urogen Pharma
―
Maravai Lifesciences Holdings
―
MBX Biosciences, Inc.
―